Advertisement

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement

Mar

04

Today In Oncology

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

CD123-Targeting ADC Shows Activity in AML and BPDCN

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers

Advertisement

© 2026 HSP News Service, L.L.C.